After Buying HUB and Partnering with Promega, MilliporeSigma Charts Growth Path in Organoids
Drug developers and their contract development and manufacturing organizations (CDMOs) moving away from animal testing—whether for financial, regulatory, or moral reasons—are increasingly finding an alternative in organoid models designed to uncover …